470 related articles for article (PubMed ID: 31131841)
1. Lenvatinib mesylate to treat hepatocellular carcinoma.
Ielasi L; Tovoli F; Piscaglia F
Drugs Today (Barc); 2019 May; 55(5):305-313. PubMed ID: 31131841
[TBL] [Abstract][Full Text] [Related]
2. Lenvatinib: a potential breakthrough in advanced hepatocellular carcinoma?
Oikonomopoulos G; Aravind P; Sarker D
Future Oncol; 2016 Feb; 12(4):465-76. PubMed ID: 26785762
[TBL] [Abstract][Full Text] [Related]
3. Regorafenib for the treatment of hepatocellular carcinoma.
Tovoli F; Granito A; De Lorenzo S; Bolondi L
Drugs Today (Barc); 2018 Jan; 54(1):5-13. PubMed ID: 29569657
[TBL] [Abstract][Full Text] [Related]
4. Lenvatinib and its use in the treatment of unresectable hepatocellular carcinoma.
Baxter MA; Glen H; Evans TR
Future Oncol; 2018 Aug; 14(20):2021-2029. PubMed ID: 29783903
[TBL] [Abstract][Full Text] [Related]
5. Lenvatinib as a therapy for unresectable hepatocellular carcinoma.
Spallanzani A; Orsi G; Andrikou K; Gelsomino F; Rimini M; Riggi L; Cascinu S
Expert Rev Anticancer Ther; 2018 Nov; 18(11):1069-1076. PubMed ID: 30220234
[TBL] [Abstract][Full Text] [Related]
6. Optimal management of patients with hepatocellular carcinoma treated with lenvatinib.
Ikeda M; Kobayashi M; Tahara M; Kaneko S
Expert Opin Drug Saf; 2018 Nov; 17(11):1095-1105. PubMed ID: 30264594
[TBL] [Abstract][Full Text] [Related]
7. Lenvatinib: A Review in Hepatocellular Carcinoma.
Al-Salama ZT; Syed YY; Scott LJ
Drugs; 2019 Apr; 79(6):665-674. PubMed ID: 30993651
[TBL] [Abstract][Full Text] [Related]
8. Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy.
Zhao Y; Zhang YN; Wang KT; Chen L
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188391. PubMed ID: 32659252
[TBL] [Abstract][Full Text] [Related]
9. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.
Vogel A; Qin S; Kudo M; Su Y; Hudgens S; Yamashita T; Yoon JH; Fartoux L; Simon K; López C; Sung M; Mody K; Ohtsuka T; Tamai T; Bennett L; Meier G; Breder V
Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):649-658. PubMed ID: 34087115
[TBL] [Abstract][Full Text] [Related]
10. Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib.
Brunetti O; Gnoni A; Licchetta A; Longo V; Calabrese A; Argentiero A; Delcuratolo S; Solimando AG; Casadei-Gardini A; Silvestris N
Medicina (Kaunas); 2019 Oct; 55(10):. PubMed ID: 31640191
[TBL] [Abstract][Full Text] [Related]
11. Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma.
Kim S; Kim KH; Kim BK; Park JY; Ahn SH; Kim DY; Kim SU
J Gastroenterol Hepatol; 2021 May; 36(5):1317-1325. PubMed ID: 33217054
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib
Kuzuya T; Ishigami M; Ito T; Ishizu Y; Honda T; Ishikawa T; Fujishiro M
Anticancer Res; 2020 Apr; 40(4):2283-2290. PubMed ID: 32234927
[TBL] [Abstract][Full Text] [Related]
13. Review article: systemic treatment of hepatocellular carcinoma.
Pinter M; Peck-Radosavljevic M
Aliment Pharmacol Ther; 2018 Sep; 48(6):598-609. PubMed ID: 30039640
[TBL] [Abstract][Full Text] [Related]
14. Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review.
Lim H; Ramjeesingh R; Liu D; Tam VC; Knox JJ; Card PB; Meyers BM
J Natl Cancer Inst; 2021 Feb; 113(2):123-136. PubMed ID: 32898239
[TBL] [Abstract][Full Text] [Related]
15. Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost-Utility Analysis.
Kim JJ; McFarlane T; Tully S; Wong WWL
Oncologist; 2020 Mar; 25(3):e512-e519. PubMed ID: 32162815
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia.
Saiyed M; Byrnes J; Srivastava T; Scuffham P; Downes M
Clin Drug Investig; 2020 Dec; 40(12):1167-1176. PubMed ID: 33140194
[TBL] [Abstract][Full Text] [Related]
17. FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma.
Nair A; Reece K; Donoghue MB; Yuan WV; Rodriguez L; Keegan P; Pazdur R
Oncologist; 2021 Mar; 26(3):e484-e491. PubMed ID: 33044793
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
[TBL] [Abstract][Full Text] [Related]
19. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
Liu Z; Lin Y; Zhang J; Zhang Y; Li Y; Liu Z; Li Q; Luo M; Liang R; Ye J
J Exp Clin Cancer Res; 2019 Nov; 38(1):447. PubMed ID: 31684985
[TBL] [Abstract][Full Text] [Related]
20. Donafenib in hepatocellular carcinoma.
Chen R; Ielasi L; di Carlo A; Tovoli F
Drugs Today (Barc); 2023 Feb; 59(2):83-90. PubMed ID: 36811408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
